|
1
|
Banales JM, Cardinale V, Carpino G,
Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes
SJ, Fouassier L, et al: Expert consensus document:
Cholangiocarcinoma: Current knowledge and future perspectives
consensus statement from the European network for the study of
cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol.
13:261–280. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ghouri YA, Mian I and Blechacz B: Cancer
review: Cholangiocarcinoma. J Carcinog. 14:12015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ahn DH and Bekaii-Saab T: Biliary cancer:
Intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma
vs. gallbladder cancers: Classification and therapeutic
implications. J Gastrointest Oncol. 8:293–301. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Blechacz B: Cholangiocarcinoma: Current
knowledge and new developments. Gut Liver. 11:13–26. 2017.
View Article : Google Scholar :
|
|
5
|
Rizvi S, Khan SA, Hallemeier CL, Kelley RK
and Gores GJ: Cholangiocarcinoma-evolving concepts and therapeutic
strategies. Nat Rev Clin Oncol. 15:95–111. 2018. View Article : Google Scholar
|
|
6
|
Chun YS and Javle M: Systemic and adjuvant
therapies for intrahepatic cholangiocarcinoma. Cancer Control.
24:10732748177292412017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee J, Park SH, Chang HM, Kim JS, Choi HJ,
Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, et al: Gemcitabine and
oxaliplatin with or without erlotinib in advanced biliary-tract
cancer: A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 13:181–188. 2012. View Article : Google Scholar
|
|
8
|
Goff LW, Cardin DB, Whisenant JG, Du L,
Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J,
et al: A phase I trial investigating pulsatile erlotinib in
combination with gemcitabine and oxaliplatin in advanced biliary
tract cancers. Invest New Drugs. 35:95–104. 2017. View Article : Google Scholar :
|
|
9
|
Uenishi T, Yamamoto T, Takemura S and Kubo
S: Surgical treatment for intrahepatic cholangiocarcinoma. Clin J
Gastroenterol. 7:87–93. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sabharwal SS and Schumacker PT:
Mitochondrial ROS in cancer: Initiators, amplifiers or an Achilles'
heel? . Nat Rev Cancer. 14:709–721. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pizzino G, Irrera N, Cucinotta M, Pallio
G, Mannino F, Arcoraci V, Squadrito F, Altavilla D and Bitto A:
Oxidative stress: Harms and benefits for human health. Oxid Med
Cell Longev. 2017.8416763:2017.
|
|
12
|
Cohen Z, Maimon Y, Samuels N and Berger R:
Role of reactive oxygen species in the anticancer activity of
botanicals: Comparing sensitivity profiles. Oncol Lett.
13:2642–2648. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Trachootham D, Alexandre J and Huang P:
Targeting cancer cells by ROS-mediated mechanisms: A radical
therapeutic approach? . Nat Rev Drug Discov. 8:579–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moloney JN and Cotter TG: ROS signalling
in the biology of cancer. Semin Cell Dev Biol. 80:50–64. 2018.
View Article : Google Scholar
|
|
15
|
Gorrini C, Harris IS and Mak TW:
Modulation of oxidative stress as an anticancer strategy. Nat Rev
Drug Discov. 12:931–947. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin S, Li Y, Zamyatnin AA Jr, Werner J and
Bazhin AV: Reactive oxygen species and colorectal cancer. J Cell
Physiol. 233:5119–5132. 2018. View Article : Google Scholar
|
|
17
|
Huang H, Xie H, Pan Y, Zheng K, Xia Y and
Chen W: Plumbagin triggers ER stress-mediated apoptosis in prostate
cancer cells via induction of ROS. Cell Physiol Biochem.
45:267–280. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang L, Li J, Zong L, Chen X, Chen K,
Jiang Z, Nan L, Li X, Li W, Shan T, et al: Reactive oxygen species
and targeted therapy for pancreatic cancer. Oxid Med Cell Longev.
2016.1616781:2016.
|
|
19
|
Sharma V, Joseph C, Ghosh S, Agarwal A,
Mishra MK and Sen E: Kaempferol induces apoptosis in glioblastoma
cells through oxidative stress. Mol Cancer Ther. 6:2544–2553. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang C, Lv H, Yang W, Li T, Fang T, Lv G,
Han Q, Dong L, Jiang T, Jiang B, et al: SVCT-2 determines the
sensitivity to ascorbate-induced cell death in cholangiocarcinoma
cell lines and patient derived xenografts. Cancer Lett. 398:1–11.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Möhler H, Pfirrmann RW and Frei K:
Redox-directed cancer therapeutics: Taurolidine and Piperlongumine
as broadly effective antineoplastic agents (Review). Int J Oncol.
45:1329–1336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gong D and Ferrell JE Jr: The roles of
cyclin A2, B1, and B2 in early and late mitotic events. Mol Biol
Cell. 21:3149–3161. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Makhov P, Golovine K, Teper E, Kutikov A,
Mehrazin R, Corcoran A, Tulin A, Uzzo RG and Kolenko VM:
Piperlongumine promotes autophagy via inhibition of Akt/mTOR
signalling and mediates cancer cell death. Br J Cancer.
110:899–907. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng J, Son DJ, Gu SM, Woo JR, Ham YW,
Lee HP, Kim WJ, Jung JK and Hong JT: Piperlongumine inhibits lung
tumor growth via inhibition of nuclear factor kappa B signaling
pathway. Sci Rep. 6:263572016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sur S and Agrawal DK: Phosphatases and
kinases regulating CDC25 activity in the cell cycle: Clinical
implications of CDC25 overexpression and potential treatment
strategies. Mol Cell Biochem. 416:33–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Choi HJ, Fukui M and Zhu BT: Role of
cyclin B1/Cdc2 up-regulation in the development of mitotic
prometaphase arrest in human breast cancer cells treated with
nocodazole. PLoS One. 6:pp. e243122011, View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Georgakilas AG, Martin OA and Bonner WM:
p21: A two-faced genome guardian. Trends Mol Med. 23:310–319. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tanida I, Ueno T and Kominami E: LC3 and
autophagy. Methods Mol Biol. 445:77–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Harshbarger W, Gondi S, Ficarro SB, Hunter
J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA and
Westover KD: Structural and biochemical analyses reveal the
mechanism of glutathione S-Transferase Pi 1 inhibition by the
anti-cancer compound piperlongumine. J Biol Chem. 292:112–120.
2017. View Article : Google Scholar :
|
|
30
|
Piska K, Gunia-Krzyżak A, Koczurkiewicz P,
Wójcik-Pszczoła K and Pękala E: Piperlongumine (piplartine) as a
lead compound for anticancer agents-Synthesis and properties of
analogues: A mini-review. Eur J Med Chem. 156:13–20. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thongsom S, Suginta W, Lee KJ, Choe H and
Talabnin C: Piperlongumine induces G2/M phase arrest and apoptosis
in cholangiocarcinoma cells through the ROS-JNK-ERK signaling
pathway. Apoptosis. 22:1473–1484. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Verbon EH, Post JA and Boonstra J: The
influence of reactive oxygen species on cell cycle progression in
mammalian cells. Gene. 511:1–6. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Perry JA and Kornbluth S: Cdc25 and wee1:
Analogous opposites? . Cell Div. 2:122007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee HN, Jin HO, Park JA, Kim JH, Kim JY,
Kim B, Kim W, Hong SE, Lee YH, Chang YH, et al: Heme oxygenase-1
determines the differential response of breast cancer and normal
cells to piperlongumine. Mol Cells. 38:327–335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kongpetch S, Puapairoj A, Ong CK,
Senggunprai L, Prawan A, Kukongviriyapan U, Chan-On W, Siew EY,
Khuntikeo N, The BT and Kukongviriyapan V: Haem oxygenase 1
expression is associated with prognosis in cholangiocarcinoma
patients and with drug sensitivity in xenografted mice. Cell
Prolif. 49:90–101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen YF, Liu H, Luo XJ, Zhao Z, Zou ZY, Li
J, Lin XJ and Liang Y: The roles of reactive oxygen species (ROS)
and autophagy in the survival and death of leukemia cells. Crit Rev
Oncol Hematol. 112:21–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Azad MB, Chen Y and Gibson SB: Regulation
of autophagy by reactive oxygen species (ROS): Implications for
cancer progression and treatment. Antioxid Redox Signal.
11:777–790. 2009. View Article : Google Scholar
|
|
38
|
Wang H, Wang Y, Gao H, Wang B, Dou L and
Li Y: Piperlongumine induces apoptosis and autophagy in leukemic
cells through targeting the PI3K/Akt/mTOR and p38 signaling
pathways. Oncol Lett. 15:1423–1428. 2018.PubMed/NCBI
|
|
39
|
Chen SY, Liu GH, Chao WY, Shi CS, Lin CY,
Lim YP, Lu CH, Lai PY, Chen HR and Lee YR: Piperlongumine
suppresses proliferation of human oral squamous cell carcinoma
through cell cycle arrest, apoptosis and senescence. Int J Mol Sci.
17:pp. pii E6162016
|
|
40
|
Yamaguchi Y, Kasukabe T and Kumakura S:
Piperlongumine rapidly induces the death of human pancreatic cancer
cells mainly through the induction of ferroptosis. Int J Oncol.
52:1011–1022. 2018.PubMed/NCBI
|
|
41
|
Su M, Mei Y and Sinha S: Role of the
crosstalk between autophagy and apoptosis in cancer. J Oncol.
2013.102735:2013.
|
